506414 — Fermenta Biotech Balance Sheet
0.000.00%
- IN₹7.68bn
- IN₹8.08bn
- IN₹4.69bn
- 88
- 51
- 56
- 76
Annual balance sheet for Fermenta Biotech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 444 | 335 | 605 | 597 | 715 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 805 | 959 | 566 | 866 | 1,278 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 3,096 | 3,140 | 2,530 | 2,418 | 3,352 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2,194 | 2,373 | 2,585 | 2,535 | 2,322 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 6,871 | 7,068 | 6,358 | 5,478 | 6,145 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2,093 | 2,071 | 2,087 | 1,733 | 2,119 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 3,265 | 3,347 | 3,212 | 2,590 | 2,518 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 3,606 | 3,721 | 3,146 | 2,889 | 3,627 |
| Total Liabilities & Shareholders' Equity | 6,871 | 7,068 | 6,358 | 5,478 | 6,145 |
| Total Common Shares Outstanding |